The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, raised $221 million by offering 13.8 million shares at $16, the high end of the $14 to $16 range. Talis originally filed to sell 10 million shares, before...read more
Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Menlo Park, CA-based company now plans to raise $173 million by offering 11.5 million...read more
Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, announced terms for its IPO on Monday. The Menlo Park, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to...read more
US IPO Weekly Recap: IPO frenzy brings the year’s largest deal and biggest pop in a 17 IPO week
The IPO frenzy continued this past week as 17 IPOs and 26 SPACs entered the public market. Headlining the week were dating app Bumble (BMBL), which completed the year's largest deal so far, and Chinese cloud services provider ...read more
COVID-19 test developer Talis Biomedical prices upsized IPO at $16 high end
Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, raised $221 million by offering 13.8 million shares at $16, the high end of the $14 to $16 range. Talis originally filed to sell 10 million shares, before...read more
Diagnostic testing developer Talis Biomedical raises deal size by 15% ahead of $173 million IPO
Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Menlo Park, CA-based company now plans to raise $173 million by offering 11.5 million...read more
Diagnostic testing developer Talis Biomedical sets terms for $150 million IPO
Talis Biomedical, which is developing diagnostic tests for COVID-19 and other infectious diseases, announced terms for its IPO on Monday. The Menlo Park, CA-based company plans to raise $150 million by offering 10 million shares at a price range of $14 to...read more